The alert, identified as No. 043/2024, was published on NAFDAC’s official website.
It revealed that the counterfeit drugs were manufactured in February and June 2023, with expiration dates in May and June 2026.
The affected batch number is 7225119, and the NAFDAC registration number is A11-0299. The tablets were produced by Strides Arcolab Limited, located at 36/7, Suragajakkanahalli, Indlavadi Cross, Anekal Taluk, Bangalore, India.
NAFDAC has instructed all zonal directors and state coordinators to conduct surveillance and remove counterfeit products from the market.
The agency has also urged importers, distributors, retailers, healthcare professionals, and caregivers to remain vigilant and refrain from importing, distributing, selling, or using the counterfeit tablets.
In its advisory, NAFDAC emphasized the importance of sourcing medical products from authorized and licensed suppliers.
It also recommended thorough checks to verify the authenticity and condition of products.
NAFDAC encouraged healthcare professionals and consumers to report any suspicions of counterfeit or substandard medicines and medical devices to the nearest NAFDAC office.
To report concerns, the public can call NAFDAC’s helpline at 0800-162-3322 or email: sf.alert@nafdac.gov.ng.
“Healthcare professionals and patients are similarly encouraged to report adverse or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng.,” it said